2 33 Abstract 34 This paper applies objective methods to explore the technological origins of the widely acclaimed 35 CRISPR breakthrough in the technological domain of genome engineering. Previously developed 36 patent search techniques are first used to recover a set of patents that well-represent the 37 genome editing domain before CRISPR. Main paths are then determined from the citation 38 network associated with this patent set allowing identification of the three major knowledge 39 trajectories. The most significant of these trajectories for CRISPR involves the core of genome 40 editing with less significant trajectories involving cloning and endonuclease specific 41 developments. The major patents on the core trajectory are consistent with qualitative expert 42 knowledge of the topical area. A second set of patents that we call the CRISPR roots are obtained 43 by finding the patents directly cited by the recent CRISPR patents along with patents cited by that 44 set of patents. We find that the CRISPR roots contain 8 key patents from the genome engineering 45 main path associated with restriction endonucleases and the expected strong connection of 46 CRISPR to prior genome editing technology such as Zn finger nucleases. Nonetheless, analysis of 47 the full CRISPR roots shows that a very wide array of technological knowledge beyond genome 48 engineering has contributed to achieving the CRISPR breakthrough. Such breadth in origins is not 49 surprising since "spillover" is generally perceived as important and previous qualitative studies 50 of CRISPR have shown not only technological breadth in origins but scientific breadth as well. In 51 addition, we find that the estimated rate of functional performance improvement of the CRISPR 52 roots set is about 9% per year compared to the genome engineering set (~4 % per year). These 53 estimates indicate below average rates of improvement and may indicate that CRISPR (and 54 perhaps yet undiscovered) genome engineering developments could evolve in effectiveness over 55 an upcoming long rather than short time period. 56 57 Introduction
The current research utilizes two sets of US patents for the quantitative empirical study. 126 The first set of patents represent the genome engineering domain and are retrieved using the 127 Classification Overlap Method (COM) (18,19) which utilizes two different classification systems 128 to obtain highly relevant patents. In this study, the COM procedure was implemented in 5 steps. 129 (step 1) Preparation of Pre-set patents: This step can utilize representative key inventors, 130 assignees, or patents. In the current study, we utilized 58 key patents found by searching for 131 some known inventors of genome editing technologies. (step 2) Identification of classes in two 132 distinct classification systems: we chose the US Patent Classification (UPC), and the Cooperative 133 Patent Classification (CPC) as the systems. Mean Precision-Recall (18, 19) was used as a metric to 134 identify the relevant classes in UPC and in CPC. (step 3) Patents that are common to classes in 135 UPC and in CPC identified in Step 2 are retrieved; (step 4) Test of relevancy: A sample of retrieved 136 patents (most cited 100 patents and 200 randomly selected patents from the remaining) were 137 read (mostly just titles and abstracts) by the investigators to determine relevancy of the patent 138 set. (step 5) For completeness, the classes were checked to ensure that more than 75% of the 58 139 key patents were included in the retrieved set of patents. 140 To generate the final genome engineering patent set, the steps above were applied to all 141 granted US patents from 1970/01/01 to 2018/01/15 available in Patsnap, a commercial patent 142 database (35). The 58 key patents for Step 1 were identified by a domain expert through 143 literature review of patents found by searching for known major participants in genome editing 144 technologies. The 58 patents uncovered include 28 patents related to zinc finger nuclease (ZFN), 145 8 patents for transcription activator-like nucleases (TALEN), 6 patents for meganuclease and 16 146 patents for CRISPR. An in-depth study of a sample of patents in the genome editing patents 147 showed that significant number of the patents were classified in many classes. For example, 148 patent number US8865406 is classified into 14 UPC classes, which is unlike what is typically seen 149 in other technological domains such as Solar Power, Batteries, and Integrated Circuits (average 150 is 3.2 UPC classes). Further, we also observed that the Mean-Precision Recall value of UPC and 151 CPC classes decayed slowly as compared to other domains. This implied that potentially relevant 152 patents were widely dispersed across many classes both in UPC and in CPC. This made it 153 necessary to include multiple classes both in UPC and in CPC to attain adequate coverage of 154 patents and dictated that reading titles and abstracts was done in multiple iterations. 155 156 The main path methodology provides the means to identify important patents in the 216 technological domain and pathways through which the technological knowledge diffused in the 217 domain. The method originated to understand the evolution of scientific fields through study of 218 citations by scientific publications (12). The methodology was adapted and modified to 219 investigate the evolution of knowledge in many technological domains (13-17). Most recently, 220 the method has been optimized to produce simpler main paths, while capturing a greater number 221 of important patents (17). Labeled as genetic backward-forward path (GBFP) analysis, the 222 optimized method consists of four steps shown in Figure 4 : assembling/collecting a patent set, 223 constructing a citation network within the patent set, measuring knowledge persistence of the 224 patents to identify genetically high-persistent patents, and tracing main paths (forward and 225 backward) from the genetically high-persistent patents. 226
To implement the method for the genome engineering and CRISPR roots patent sets, the 227 patent network is constructed using the citations made by the patents in the sets. It is noted that 228 we consider citations only within the patent set; any citations outside the patent set are ignored. 229 To estimate the persistence of knowledge (15,17) contained in each patent, the patent network 230 is first ordered using the citations into n layers (visualize that the patents initially cited are on the 231 left) and then knowledge persistence is estimated for each patent in the leftmost layer (layer 1). 232 The process is repeated successively for the subsequent layers moving to the right (layers 2, 3, 233 4…) after eliminating all the layers to the left of the layer in question. This algorithm estimates 234 two types of persistence values (0 to 1 after normalizing) for each patent in the network: global 235 persistence (GP) and local persistence (LP). The GP of a patent is estimated to gauge the 236 importance of a patent in the entire network whereas LP is estimated to gauge the importance 237 of patents in each layer. The layer persistence plays a significant role in identifying and retaining 238 important patents, which are recent, and hence, have not had a chance for their lineage to 239 evolve. The high-persistent (GP > 0.3 and LP > 0.8) patents then become the origin for tracing for 240 the main paths, both backward and forward (17). We adopt GBFP analysis to investigate the 241 evolution of CRISPR within the genome engineering domain. Specifically, we use this 242 methodology to identify important patents in genome engineering which preceded the CRISPR 243 technology. By reading these important patents we are also able to identify technology clusters 244 within genome engineering that preceded CRISPR. 245 246 Fig. 4 Steps for genetic backward-forward path analysis (GBFP) adapted from (17) 247 248 Estimation of patent centrality and annual improvement rate (k) 249
The estimation of annual improvement rate for a set of patents starts-as does the main 250 path method just described-with the patent citation network. The centrality of a patent is 251 analogous to betweenness centrality in network analysis, and provides a measure of the 252 influence a node, in our case the patent, has over flow of information (in our case, the 253 technological knowledge) through the network. Our calculation of the information centrality can 254 again be traced to Hummon and Doreian (12) and their introduction of search path node pairs 255 (SPNP) as a metric to compute the centrality of a focal paper in a scientific paper citation network. 256 The SPNP for a focal patent (say, patent B) in a patent citation network calculates the number of 257 pathways originating from one patent (say, patent A) to another one (patent C) in the network 258 and passing through the focal patent (patent B). The higher the number of pathways traversing 259 through the focal patent the higher the centrality of the focal patent, indicating the importance 260 of the focal patent in the patent citation network. Since each patent can be interpreted as 261 containing some original technological knowledge, the centrality provides a sense of the 262 importance of the original knowledge introduced by the focal patent for the downstream 263 patents. Triulzi et al (33) normalized the SPNP to account for the variations inherent in the 264 patenting system (for example, citation practices between fields, and particularly over time), 265 which make raw centrality values of patents across domains and between two different time 266 periods non-comparable. To control for these variations, the computed centrality of a patent is 267 compared with the expected value of the centrality of the same patent in appropriately 268 randomized models of the citation network (33). The centrality calculated was for the citation 269 network of all US utility patents granted from 1976 until 2015. Triulzi et al further find that the 270 mean normalized centrality of a patent set representing a specific technological domain is a 271 reliable predictor of its annual rate of improvement (k). They arrive at this conclusion by a Monte 272 Carlo cross-validation exercise between empirically observed k for the 30 diverse technological 273 domains (28, 30) and their corresponding mean normalized centrality of the patent sets for the 274 same 30 technological domains. Their regression model developed considering 30 technological 275 domains is shown below:
276
= ( -5.01885 + 6.15987 * ) * 2 2 277 Where k i represents the annual rate of improvement for domain i, C i the mean normalized 278 centrality of the patent sets for the domain i, and σ i the standard deviation of C i . We have 279 adopted their regression model to estimate the annual rate of improvement for the genome 280 engineering and CRISPR roots patent sets. Indeed, we used the centrality calculations developed 281 by Triulzi et al (33) for the patents in our patent sets to calculate the mean for the two sets which 282 we treated as domains. 283
284 Results 285 Genome engineering main path 286 Figure 5 gives the results of applying the main path methods described in the previous 287 section to the genome engineering patent set. The main path is a network with three principal 288 components (GE1, 2 and 3). While all relate to the development of enzymes to bind and cleave 289 DNA, GE1 and GE3 relate to the production of restriction endonucleases (REs) for general 290 molecular biology applications whereas the larger GE2 path relates specifically to core genome 291 editing development. 292
GE3 has the oldest patents dating to the mid-1970's. The initial patents (1, 2 and 293 3), all assigned to Rikagaku, Japan, specify methods for purifying endogenous nucleases from 294 bacterial cells. Subsequent patents in this path from the 80's and the early 90's relate to methods 295 of producing specific REs. 296 Patent 13 (US5200333) belongs to GE1 and it also initiates GE2. This patent relates to 297 improvements in methods of producing REs by selection of bacterial cells expressing methylase 298 enzymes that confer resistance to the RE produced. The GE1 path extends this with further 299 enhancements to the methodology of producing REs (patents 29, 30, 31,32) and applying these 300 improvements for producing specific REs (patents 33 and 34). Most of the patents in GE1 are 301 assigned to New England Biolabs indicating a significant role for them during the 1990's 302 improving the methods of RE production. GE2 is the path of direct relevance to genome engineering. Based on the same 313 improvements on RE production described in patent 13, GE2 combines these with major 314 advances in creating synthetic novel REs that recognize rarer DNA targets using ZFNs and TALENs 315 and ultimately CRISPR complexes that are applicable to genome engineering. This path is 316 analyzed further in Figure 6 showing the key patents in the development of genome engineering 317 that underlie the emergence of CRISPR. 
326
Patents 9 and 11 (labeled cluster B in figure 6) from the early 90's describe a fundamental 327 step forward, taken by Chandrasegaran's group at Johns Hopkins University, towards the goal of 328 genome engineering: The separation of FokI restriction endonuclease (RE) into two distinct 329 domains, one that binds its cognate target DNA sequence and the other containing the nuclease 330 activity that cleaves DNA. This invention led to the possibility that the nuclease activity of FokI 331 could be fused to alternative DNA binding domains to create so called "hybrid REs" with novel, 332 and potentially rare DNA target sequences useful for genome engineering in large animal and 333 plant genomes (36).
334
A significant challenge in producing hybrid REs in bacteria was that they were potentially 335 lethal to their host bacteria if the latter contained target sequences in their genome (36). Patents 336 12 and 14 from the mid-90's describe improvements to bacterial hybrid RE synthesis by co-337 expressing DNA ligases and/or expressing the hybrid REs on inducible plasmids to mitigate this 338 risk. Patent 15 describes the use of these methods to produce hybrid REs for genome editing as 339 well as other proteins that bind specific target DNA sequences for other applications. Patents 12, 340 14 and 15 are thus labeled as a cluster (C in the figure) which we refer to as Hybrid REs. 341
Another key step forward was the elucidation of the structure of zinc finger transcription 342 factors revealing their modular zinc finger (ZF) structures responsible for DNA sequence 343 specificity. This led to the idea that ZFs could be fused to a nuclease to create a hybrid RE with a 344 novel DNA sequence specificity (36, 38, 39). In the late 90's and early 00's, patents 10 and 16 345 from Sangamo Biosciences describe the foundational invention of hybrid REs that fuse zinc finger 346 DNA-binding domains with the FokI nuclease domain to create a zinc-finger nuclease (ZFN) 347 capable of regulating or inactivating a target gene in its normal chromosomal context. These two 348 patents and patent 17 constitute the ZFN labeled cluster D in figure 6. 349
The later discovery of transcription activator-like effectors (TALE) bacterial proteins that 350 could, like zinc fingers, be engineered to create novel DNA binding specificities led to an 351 analogous approach of fusing TALE binding domains to nucleases (36, 38, 39 In the late 1990's, the discovery that the FokI nuclease is comprised of two monomers 357 that require dimerization for nuclease activity led to the invention (Patent 17) of ZFN pairs 358 comprising two monomers, each with a FokI half-cleavage domain and a zinc finger domain. ZFN 359 pairs provided greater DNA target specificity because they require correct binding of two 360 separate zinc fingers to reconstitute the nuclease activity of the FokI dimer (36). 361
In the past decade, patents 18, 19 and 20 describe the application of ZFN and TALEN 362 genome engineering technologies for specific therapeutic purposes, such as to modulate PD1 363 gene expression for cancer immunotherapy (patent 18) or severe combined immunodeficiency 364 (SCID) related genes (patents 19 and 20). Patents 24, 25, 27 and 28 from Factor Bioscience all 365 describe extending the therapeutic application of ZFN, TALENs or CRISPR by therapeutic delivery 366 of a synthetic RNA encoding the genome editing enzymes rather than DNA. In this way, the 367 therapeutic nucleic acid is not incorporated into the genome potentially reducing the risk of 368 unwarranted mutagenesis and limiting the therapeutic exposure to the lifespan of the RNA 369 molecule. 370
The 20 patents just discussed and particularly the 12 (see Figure 6 ) that the technique 371 identified as high persistence patents are clearly important patents as identified by other 372 observers. The main path technique indicates that they are the most important in the overall 373 development of genome editing prior to CRISPR. Therefore, we regard this small set of patents 374 as the core technology preceding the CRISPR breakthrough but we do not regard all the rest of 375 the 1373 patents in the set as unimportant since it is highly likely there are other quite important 376 patents in the set. 377 378 CRISPR Roots Patents 379
The CRISPR roots patent set is different from the genome engineering patent set as it 380 does not focus on a specific technical area (genome engineering) but instead backwardly traces 381 all patented knowledge sources that have contributed to the emergence of CRISPR technology. 382 Recall that the genome engineering patent set was carefully limited to chosen patent classes 383 whereas the CRISPR roots set was subject to no such constraint. Additionally, all citations outside 384 this selected set were ignored for the genome engineering main path analysis whereas the 385 CRISPR roots includes all citations from the initial set of patents. The well-known and important 386 phenomenon known as spillover means that the roots patent set will reflect broad sources of 387 knowledge not included in the genome engineering domain. 388
The difference in breadth between the CRISPR roots and the genome engineering patent 389 set is visible in the main path derived from the roots patent set. Figure 7 shows the result from 390 application of the main path method to that patent set. Since this patent set is obtained starting 391 with the citations by the currently published CRISPR patents, this knowledge network is 392 constrained to end on the right at the CRISPR patents and the main path identifies patents that 393 were particularly important in citations cascading back from these patents. The reasoning to 394 develop this non-usual main path was simply to reduce the 1300+ patent set to the 50 most 395 important ones so that it was possible to read and sort the patents. 396 397 Figure 7 . Main Path for the CRISPR roots showing patents on this knowledge trajectory from the CRISPR patents 398 (gen 0), the patents cited by the CRISPR patents (gen 1) and the patents cited by gen 1 patents but not by CRISPR 399 patents (gen 2). Three main paths (CR1, CR2, and CR3) have been identified. CR1: Technologies for introducing 400 nucleic acid into mammalian cells; CR2: Genome engineering (including protein binding domains, ZFN and CRISPR); 401 CR3: DNA finger printing and PCR. Labeled nodes represent patents shown in the table below the main path 402 diagram. The node numbers increase along the time axis. 403
Like Figure 5 , the main path network in Figure 7 also can be interpreted as consisting of 404 three knowledge trajectories. At the top of the diagram is a large sequence of patents (CR1) that 405 are concerned with delivery or the introduction of nucleic acid to mammalian cells. In the bottom 406 part of Figure 7 are a set of patents (CR3) that involve DNA fingerprinting and demonstrate the 407 pervasive impact of PCR on biotechnology as it emerges in the CRISPR context. The central main 408 path or knowledge trajectory is genome engineering (CR2) which is connected to CR3 in 3 places 409 and to CR1 in the link between patents 34 and 40. The presence of CR1 and CR3 paths in the roots 410 main path demonstrates the broader scope of the CRISPR roots compared with the genome 411 editing patent set. The patents in these paths were not in the genome engineering set by design 412 but are shown in Figure 7 to play a prominent "spillover" role in the emergence of CRISPR. 413 Table 1 shows the ten patents with the highest normalized centrality (maximum = 1) from 414 the CRISPR roots. Demonstrating the relative breadth in the CRISPR nucleus compared to the 415 genome engineering patent set is the fact that none of these patents are in the genome 416 engineering set. Instead, they include very important patents from the osmotic device domain, 417 the ultrasound apparatus domain, nucleic acid methodology, crystal protein technology, and the 418 drug delivery domain. With a minimum normalized centrality of > 0.986, these patents are highly 419 important in their own domain and likely represent indirect or spillover technology essential to 420 the development of CRISPR but are not on the genome engineering main path. Indeed, the 421 second ranked patent in Table 1 is the very important/central PCR patent by Kary Mullis. It is 422 probable that without PCR, there would be no CRISPR but this does not signify that this patent is 423 on the main knowledge accumulation path leading to CRISPR. This result is similar to the broad 424 scientific input that enabled CRISPR identified by Lander (9), by Doudna and Sternberg (10) and 425 by Urnov (11) but the patents in Table 1 Although, as just emphasized, there are differences in the collection techniques and 433 therefore in the results shown in Figures 5/6 and 7, there are also important similarities since 434 both reflect the genome engineering work that preceded CRISPR. In this regard, we note that 5 435 of the top institutional owners of patents in the genome editing set are also in the top 436 institutional owners of patents in the CRISPR roots set (compare Figure 2B and Figure 3B ). 437 Moreover, Table 2 shows 8 key patents in the main path of the genome engineering set that are 438 also in CRISPR roots set. All 8 patents listed in Table 2 that are found in the CRISPR nucleus are 439 also found in the GE2 (core genome editing) knowledge trajectory from the main path analysis 440 of that domain. The node numbers in Table 2 are the ones given to these patents in Figure 6 441 which shows GE2 details and clusters. These 8 patents all relate to the foundational inventions 442 of genome engineering prior to the discovery of CRISPR. As described above, patents 9 and 11 443 are inventions based on the discovery that the FokI restriction endonuclease is made of two 444 separable DNA binding and cleavage domains. Patents 12, 14 and 15 describe methodological 445 improvements in producing hybrid REs, while 10, 16 and 17 are related to the development of 446 ZFNs as the first generally applicable hybrid REs for gene editing. The overlap between the 447 patent sets is further illustration of the importance of earlier genome engineering technology to 448 the development of CRISPR genome engineering despite the independent discovery of the 449 original bacterial CRISPR viral resistance mechanism and all the very important but more distant 450 knowledge represented in Table 1.  451  452 Table 2 : Eight key patents in the main path and core of genome editing which are also in the 453 CRISPR roots set. Table 3 gives the results obtained when applying the k estimation algorithm described in 458 the methods section (k is directly determined from the average centrality of the patent set) to 459 the two patent sets. The first result is that the patent sets give different estimates of k 460 (approximately x3 difference). Perhaps more significantly, both estimates are relatively low. We 461 now briefly consider these two findings. 462 463 466 467 Prior analysis of uncertainty in the k estimates (33, 34) indicates that +/-50% uncertainty 468 is a reasonable quantification for k +/-. This uncertainty in the estimate is consistent with 469 empirical measurement of k (28, 29). Thus, the x3 difference in the estimated k values is probably 470 not only due to uncertain estimates. Since these two sets of patents have large differences in 471 what is included, significant differences in k are not unreasonable and could arise in various ways. 472 One factor that appears likely to explain a large part of the differential result is the significantly 473 larger breadth of the patents in the CRISPR roots which was discussed in the preceding section 474 as reflecting the "spillover" patents in the roots that are not in the genome editing patent set. 475 Such patents were not included in the domains where the empirical correlation was established 476 (31,33) and would tend to distort k estimates for domains upwardly since patents cited from 477 "farther afield" tend to be patents that are important in carrying information-that is have 478 important new knowledge at their core-and thus have higher centrality than average. Since the 479 genome engineering patent set has considerably lower average centrality (0.27) than the entire 480 US patent set (0.5), including such patents in the set (as the roots set does) raises the overall k 481 estimate. For example, the patents in Table 1 are the highest centrality patents from the roots 482 set and were already seen as demonstrating breadth in the roots patent set. 483
Our second finding is that even the k value for the roots set is not very high in terms of 484 what we now know about k values in various domains. Indeed, the average centrality of the 485 genome engineering set is well below average (0.27) for USPTO patents and the average 486 centrality of the CRISPR roots is higher (.43) but still below average for the entire US patent set 487 which is equal to 0.5 (33).
Discussion and Conclusions

489
Our first research objective was to determine what the patent record suggests relative to 490 the relationship of CRISPR to prior technology-particularly pre-existing genome engineering. The 491 results presented here (particularly Figure 6 and Table 3) show clearly that pre-existing genome 492 engineering technology was essential to the emergence of CRISPR. There is close alignment of
